A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

This trial compares a new antibody-drug conjugate called BL-B01D1 (which delivers chemotherapy directly to cancer cells) with the standard chemotherapy drug docetaxel in patients with advanced non-small cell lung cancer that does not have the EGFR gene mutation. **You may be eligible if...** - You are 18 or older - You have locally advanced or metastatic non-small cell lung cancer without an EGFR mutation, confirmed by tissue testing - Your cancer can be measured on scans - You are in good general health (ECOG 0-1) - Your heart, liver, kidney, and blood function are adequate - Your expected survival is at least 3 months **You may NOT be eligible if...** - Your tumor has an EGFR mutation - You have severe heart problems or low heart pumping function - Your organ function is inadequate - You have unresolved side effects from prior cancer treatment Talk to your doctor to see if this trial is right for you.